W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Transparency Council

25 April, 2025

Communication of the meeting of Transparency Council No. 14/2025 on 7 April 2025

25 April, 2025

Opinion of the Transparency Council – quetiapinum

25 April, 2025

Opinion of the Transparency Council – rivastigmine

25 April, 2025

Opinion of the Transparency Council – donepezili hydrochloridum

25 April, 2025

Position of the Transparency Council – Minjuvi (tafasitamab)

25 April, 2025

Position of the Transparency Council – Omjjara (momelotinib)

25 April, 2025

Position of the Transparency Council – Fruzaqla (fruquintinib)

16 April, 2025

Opinion of the Transparency Council – posaconazole

16 April, 2025

Opinion of the Transparency Council – posaconazole

16 April, 2025

Opinion of the Transparency Council – lacosamide

16 April, 2025

Opinion of the Transparency Council – peginterferon alfa-2a

16 April, 2025

Opinion of the Transparency Council – carbamazepine

16 April, 2025

Position of the Transparency Council – Albendazol Micro Labs

16 April, 2025

Position of the Transparency Council – Xyrem (sodium oxybate)

16 April, 2025

Position of the Transparency Council – Tagrisso (osimertinib)

16 April, 2025

Opinion of the Transparency Council – Treatment of Gaucher disease type I and type III (ICD-10 E 75.2)

16 April, 2025

Position of the Transparency Council – Fabhalta (iptacopan)

14 April, 2025

The Transparency Council meeting 16/2025 on 22 April 2025

09 April, 2025

Opinion of the Transparency Council – olanzapine

09 April, 2025

Opinion of the Transparency Council – haloperidolum

09 April, 2025

Opinion of the Transparency Council – prednisonum

09 April, 2025

Position of the Transparency Council – Mestinon Retard (pyridostigmini bromidum) and Mestinon (pyridostigmini)

08 April, 2025

Communication of the meeting of Transparency Council No. 13/2025 on 31 March 2025

08 April, 2025

The Transparency Council meeting 15/2025 on 14 April 2025

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑